What's in a Drug's Name?

The Wall Street Journal reports today on the "odd corner of the federal bureaucracy" in the Food and Drug administration where names of new drugs are submitted for approval. The reviewers' job is to determine whether a proposed name is too similar to that of a drug already on the market. In more than a third of the cases reviewed last year, they decided that proposed monikers were insufficiently unique.